(Q33372106)

English

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Michael Pfreundschuh

4

object named as

Michael Pfreundschuh

0 references

object named as

Eva Hoster

3

0 references

Wolfgang Hiddemann

10

object named as

Wolfgang Hiddemann

1 reference

Europe PubMed Central

26 July 2017

7

object named as

Hannes Wandt

1 reference

Europe PubMed Central

26 July 2017

Martin Dreyling

2

object named as

Martin Dreyling

1 reference

Europe PubMed Central

26 July 2017

Michael Unterhalt

9

object named as

Michael Unterhalt

1 reference

Europe PubMed Central

26 July 2017

author name string

Christina Nickenig

1

1 reference

Europe PubMed Central

26 July 2017

Lorenz Trumper

5

1 reference

Europe PubMed Central

26 July 2017

Marcel Reiser

6

1 reference

Europe PubMed Central

26 July 2017

Eva Lengfelder

8

1 reference

Europe PubMed Central

26 July 2017

German Low-Grade Lymphoma Study Group

11

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

1 September 2006

1 reference

Europe PubMed Central

26 July 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

26 July 2017

107

1 reference

Europe PubMed Central

26 July 2017

1014-1022

1 reference

Europe PubMed Central

26 July 2017

5

1 reference

Europe PubMed Central

26 July 2017

Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

21 January 2018

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunochemotherapy in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessing the reliability of two toxicity scales: implications for interpreting toxicity data.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

A unified theory for sequential clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Cure and follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

New treatment options have changed the survival of patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Stu

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22093

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22093

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33372106&oldid=2092777199"